Short answer
Voyager Therapeutics, Inc. (VYGR) filed an 8-K current report with the SEC on May 7, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Voyager’s Q1 2026 financial and operating results are provided in Exhibit 99.1, dated May 7, 2026.
Voyager Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Voyager’s Q1 2026 financial and operating results are provided in Exhibit 99.1, dated May 7, 2026
- Investor focus: quarterly cash position, operating expenses, pipeline progress, and partnership milestones in the referenced release
- Filing signed by CEO, President, and Director Alfred Sandrock, M.D., Ph.D.
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Voyager Therapeutics, Inc. 8-K filings
Get the next VYGR 8-K as it lands
Follow VYGR for push alerts, or ask the research agent what this filing means.